XPS™ at the world’s second largest lung transplant clinic

The AKH University Hospital in Vienna, Austria, which is the world’s second largest lung transplant clinic, has decided to use the XPS™. It is estimated that delivery and installation of the XPS™ will take place at the beginning of October.

The clinic in Vienna has more than 25 years’ experience of lung transplantation and has a well-reputed lung transplant program for being a leader in the field of Ex Vivo Lung Perfusion (EVLP). Under the leadership of Professor Walter Klepetko the clinic has established itself as the second largest in the world in terms of the number of lung transplants performed (123 during 2014) and Vienna is one of the clinics that annually present ground-breaking results in the field of EVLP at international congresses.

“So far the clinic in Vienna has performed EVLP using the so-called manual STEEN Solution™ method, and is now going to explore EVLP using the XPS™ and STEEN Solution™”, says Professor Walter Klepetko.

The XPS™ is the only complete CE-marked and FDA-approved system on the market that gives the user the flexibility to perform the evaluation of lungs for transplantation using a standardized and simplified procedure. The XPS™ has achieved good clinical results in NOVEL-trial when used at leading clinics in the USA. In Europe, two clinics are currently working with the XPS-system where successful EVLP have resulted in lung transplantation. The clinic in Vienna is the third clinic to install the XPS™ in Europe so far and the company notes a continued high interest for the XPS™ in Europe.

“We are very pleased that the clinic in Vienna, which has the greatest experience of clinical EVLP with STEEN Solution™ in Europe, now starts to use the more standardized and simplified XPS™ system to facilitate the EVLP method," says Magnus Nilsson, CEO of XVIVO Perfusion.

October 8, 2015
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication on October 8, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com



Documents & Links